Australia - inglese - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; colloidal anhydrous silica; macrogol 6000; magnesium stearate; purified talc; titanium dioxide; microcrystalline cellulose; propylene glycol - tramal sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramal sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramal sr is not indicated as an as-needed (prn) analgesia.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; citric acid monohydrate; lactose monohydrate; purified talc; ascorbic acid; hypromellose; pregelatinised maize starch; butylated hydroxyanisole; titanium dioxide; iron oxide red; magnesium stearate - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; iron oxide yellow; titanium dioxide; citric acid monohydrate; purified talc; ascorbic acid; lactose monohydrate; hypromellose; microcrystalline cellulose; pregelatinised maize starch; iron oxide red; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: citric acid monohydrate; lactose monohydrate; titanium dioxide; ascorbic acid; hypromellose; purified talc; microcrystalline cellulose; iron oxide yellow; pregelatinised maize starch; iron oxide red; magnesium stearate; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxepin hydrochloride, quantity: 56.5 mg (equivalent: doxepin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; carnauba wax; purified talc; sodium starch glycollate; diethyl phthalate; magnesium stearate; titanium dioxide; indigo carmine; erythrosine; povidone - the 50mg and 75mg tablets are indicated only for the maintenance treatment of major depression. (see precautions).

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - milbemycin oxime; praziquantel - tablet - 12.5, 125.0 mg/tablet - milbemycin oxime, combinations - dogs - endectoparasiticides